MAP1LC3A and breast carcinoma: For this reason, we performed cytometric determination of LC3A/B protein levels after 24 h of breast cancer cell (MCF-7 and MDA-MB-231) treatment with the compounds in the study (EDAG-1 and EDAG-8) and the conventionally used therapeutic agent (cisplatin) at 0.5 and 1 μM concentrations.